	US RE50,313 E1
	Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell
Myung-Kwan Han, Jeonju-si (KR)
Assigned to CELLATOZ THERAPEUTICS, INC., Seongnam-si (KR)
Filed by CELLATOZ THERAPEUTICS, INC., Seongnam-si (KR)
Filed on Mar. 2, 2022, as Appl. No. 17/685,202.
Application 17/685,202 is a continuation of application No. 16/391,213, filed on Apr. 22, 2019, abandoned.
Application 16/391,213 is a continuation in part of application No. PCT/KR2018/012664, filed on Oct. 24, 2018.
Application 17/685,202 is a reissue of application No. 16/392,524, filed on Apr. 23, 2019, granted, now 10,576,106, issued on Mar. 3, 2020.
Claims priority of application No. 10-2017-0139143 (KR), filed on Oct. 25, 2017.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/34 (2015.01); A61K 35/32 (2015.01); A61P 21/00 (2006.01); C12N 5/00 (2006.01); C12N 5/0735 (2010.01); C12N 5/074 (2010.01); C12N 5/077 (2010.01); C12N 5/0775 (2010.01)

CPC A61K 35/34 (2013.01) [A61K 35/32 (2013.01); A61P 21/00 (2018.01); C12N 5/0018 (2013.01); C12N 5/0606 (2013.01); C12N 5/0653 (2013.01); C12N 5/0655 (2013.01); C12N 5/066 (2013.01); C12N 5/0662 (2013.01); C12N 5/0696 (2013.01); C12N 2501/115 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/235 (2013.01); C12N 2501/415 (2013.01); C12N 2501/727 (2013.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01); C12N 2533/52 (2013.01); C12N 2533/54 (2013.01)]

61 Claims

1. A method of preparing musculoskeletal stem cells (MSSCs), the method comprising:

culturing cells comprising embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) in a culture medium composition,

wherein the culture medium composition comprises noggin, LIF (leukemia inhibitory factor), bFGF (basic fibroblast growth factor), Wnt signaling activator, ERK (extracellular signal-regulated kinase) signaling inhibitor and TGF-β/activin/nodal signaling inhibitor,

wherein the cells, after the culturing, are MSSCs and exhibit the following characteristics:

positive for nestin (NES);

positive for Pax7;

positive for α-SMA;

negative for LIN28; and

negative for CD90.